Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 105, Issue 3, 2014, Pages 273-284

  Smith Palmer, J ^a   Brandle M ^b   Trevisan, R ^c   Orsini Federici, M ^d   Liabat, S ^e   Valentine, W ^a  

^a Ossian Health Economics and Communications   (Switzerland)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^c OSPEDALI RIUNITI   (Italy)

^d Medtronic Italia   (Italy)

^e Tolochenaz   (Switzerland)

Author keywords

Glycemic variability; Macrovascular complications; Microvascular complications

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; REACTIVE OXYGEN METABOLITE; GLUCOSE BLOOD LEVEL;

BLOOD GLUCOSE MONITORING; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY DISEASE; DIABETIC RETINOPATHY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; IN VITRO STUDY; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MICROVASCULARIZATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; POSTPRANDIAL STATE; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; UNITED KINGDOM; ANALYSIS; BLOOD; COMPLICATION; DIABETIC NEPHROPATHIES; FEMALE; MALE; METABOLISM;

BLOOD GLUCOSE; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; FEMALE; HUMANS; HYPERGLYCEMIA; MALE; OXIDATIVE STRESS; RISK FACTORS;

EID: 84921650596     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.06.007     Document Type: Review

References (64)

1. Nathan D.M., Buse J.B., Davidson M.B., Heine R.J., Holman R.R., Sherwin R., et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006, 49:1711-1721.
2. Brownlee M., Hirsch I.B. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 2006, 295:1707-1708.
3. Snell-Bergeon J.K., Roman R., Rodbard D., Garg S., Maahs D.M., Schauer I.E., et al. Glycaemic variability is associated with coronary artery calcium in men with type 1 diabetes: the Coronary Artery Calcification in Type 1 Diabetes Study. Diabet Med 2010, 27:1436-1442.
4. Mi S.H., Su G., Li Z., Yang H.X., Zheng H., Tao H., et al. Comparison of glycemic variability and glycated hemoglobin as risk factors of coronary artery disease in patients with undiagnosed diabetes. Chin Med J (Engl) 2012, 125:38-43.
5. Service F.J. Glucose variability. Diabetes 2013, 62:1398-1404.
6. Sartore G., Chilelli N.C., Burlina S., Di Stefano P., Piarulli F., Fedele D., et al. The importance of HbA1c and glucose variability in patients with type 1 and type 2 diabetes: outcome of continuous glucose monitoring (CGM). Acta Diabetol 2012, 49(Suppl. 1):S153-S160.
7. Dossett L.A., Cao H., Mowery N.T., Dortch M.J., Morris J.M., May A.K. Blood glucose variability is associated with mortality in the surgical intensive care unit. Am Surg 2008, 74:679-685.
8. Krinsley J.S. Glycemic variability: a strong independent predictor of mortality in critically ill patients. Crit Care Med 2008, 36:3008-3013.
9. Monnier L., Mas E., Ginet C., Michel F., Villon L., Cristol J.P., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006, 295:1681-1687.
10. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995, 44:968-983. The Diabetes Control and Complications Trial Research Group.
11. Lachin J.M., Genuth S., Nathan D.M., Zinman B., Rutledge B.N. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial - revisited. Diabetes 2008, 57:995-1001. DCCT/EDIC Research Group.
12. Pochinka I., Strongin L., Struchkova J. Glycaemic variability and ventricular cardiac arrhythmias in type 2 diabetic patients with chronic heart failure. 48th annual meeting of the European Association for the Study of Diabetes 2012, [abstract].
13. Mo Y., Zhou J., Li M., Wang Y., Bao Y., Ma X., et al. Glycemic variability is associated with subclinical atherosclerosis in Chinese type 2 diabetic patients. Cardiovasc Diabetol 2013, 12(January (15)):15.
14. Barbieri M., Rizzo M.R., Marfella R., Boccardi V., Esposito A., Pansini A., et al. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis 2013, 227(April (2)):349-354.
15. Liu Y., He Y. Effect of blood glucose excursions on the risk of diabetic retinopathy in type 2 diabetes. 2011 Diabetes. Conference: 71st scientific sessions of the American Diabetes Association San Diego 2011, [abstract].
16. Liu Y., Li Y., Cai H., Zhang X. The relationship between glycemic variability and macrovascular and microvascular complications in type 2 diabetes. 2011 Diabetes. Conference: 71st scientific sessions of the American Diabetes Association San Diego 2011, [abstract].
17. Yang Y., Xu L., Feng X. A positive relationship of glycemic levels with the development of diabetic cardiomyopathy and serum CTGF level in patients with type 2 diabetes. 2011 Diabetes. Conference: 71st scientific sessions of the American Diabetes Association San Diego 2011, [abstract].
18. Mo Y., Zhou J., Li M., Wang Y., Bao Y., Ma X., et al. Glycemic variability is associated with subclinical atherosclerosis in type 2 diabetes. 12th Annual Diabetes Technology Meeting 2012, [abstract].
19. Zhong Y., Zhang X.Y., Miao Y., Zhu J.H., Yan H., Wang B.Y., et al. The relationship between glucose excursion and cognitive function in aged type 2 diabetes patients. Biomed Environ Sci 2012, 25(February (1)):1-7.
20. Nathan D.M., Turgeon H., Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia 2007, 50:2239-2244.
21. Monnier L., Lapinski H., Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003, 26:881-885.
22. Kohnert K.D., Augstein P., Heinke P., Zander E., Peterson K., Freyse E.J., et al. Chronic hyperglycemia but not glucose variability determines HbA1c levels in well-controlled patients with type 2 diabetes. Diabetes Res Clin Pract 2007, 77:420-426.
23. Kohnert K.D., Augstein P., Zander E., Kohnert K.D., Augstein P., Zander E., et al. Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care 2009, 32:1058-1062.
24. Dhalla N.S., Temsah R.M., Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens 2000, 18:655-673.
25. Nalysnyk L., Hernandez-Medina M., Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab 2010, 12:288-298.
26. Siegelaar S.E., Holleman F., Hoekstra J.B., DeVries J.H. Glucose variability; does it matter?. Endocr Rev 2010, 31:171-182.
27. Muggeo M., Verlato G., Bonora E., Zoppini G., Corbellini M., de Marco R. Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus: the Verona Diabetes Study. Circulation 1997, 96:1750-1754.
28. Muggeo M., Zoppini G., Bonora E., Brun E., Bonadonna R.C., Moghetti P., et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care 2000, 23:45-50.
29. Kilpatrick E.S., Rigby A.S., Goode K., Atkin S.L. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia 2007, 50:2553-2561.
30. Lin C.C., Li C.I., Yang S.Y., Liu C.S., Chen C.C., Fuh M.M., et al. Variation of fasting plasma glucose: a predictor of mortality in patients with type 2 diabetes. Am J Med 2012, 125:416.e9-416.e18.
31. Cameron F.J., Donath S.M., Baghurst P.A. Measuring glycaemic variation. Curr Diabetes Rev 2010, 6:17-26.
32. Monnier L., Colette C., Owens D.R. Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it?. J Diabetes Sci Technol 2008, 2:1094-1100.
33. Monnier L., Wojtusciszyn A., Colette C., Owens D. The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. Diabetes Technol Ther 2011, 13:813-818.
34. Niskanen L., Virkamäki A., Hansen J.B., Saukkonen T. Fasting plasma glucose variability as a marker of nocturnal hypoglycemia in diabetes: evidence from the PREDICTIVE study. Diabetes Res Clin Pract 2009, 86:e15-e18.
35. Inzucchi S.E., DiGenio A., Zhou R., Umpierrez G. The impact of glucose variability on achievement of glycaemic control and risk of hypoglycaemia in patients with type 2 diabetes. Diabetologia. Conference: 47th annual meeting of the European Association for the Study of Diabetes, EASD 2011, [abstract].
36. Frier B.M., Schernthaner G., Heller S.R. Hypoglycemia and cardiovascular risks. Diabetes Care 2011, 34:S132-S137.
37. Lipska K.J., Kosiborod M. Hypoglycemia and adverse outcomes: marker or mediator?. Rev Cardiovasc Med 2011, 12:132-135.
38. Zoungas S., Patel A., Chalmers J., de Galan B.E., Li Q., Billot L., et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010, 363:1410-1418.
39. Seaquist E.R., Miller M.E., Bonds D.E., Feinglos M., Goff D.C., Peterson K., et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care 2012, 35:409-414.
40. Bonds D.E., Miller M.E., Bergenstal R.M., Buse J.B., Byington R.P., Cutler J.A., et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010, 340:b4909.
41. Luk A.O., Ma R.C., Lau E.S., Yang X., Lau W.W., Yu L.W., et al. Risk association of HbA1c variability with chronic kidney disease and cardiovascular disease in type 2 diabetes: prospective analysis of the Hong Kong Diabetes Registry. Diabetes Metab Res Rev 2013, 29(July (5)):384-390.
42. Penno G., Solini A., Bonora E., Fondelli C., Orsi E., Zerbini G., et al. HbA1c variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study. Diabetes Care 2013, 36(August (8)):2301-2310.
43. Hsu C.C., Chang H.Y., Huang M.C., Hwang S.J., Yang Y.C., Lee Y.S., et al. HbA1c variability is associated with microalbuminuria development in type 2 diabetes: a 7-year prospective cohort study. Diabetologia 2012, 55(December (12)):3163-3172.
44. Rodríguez-Segade S., Rodríguez J., García López J.M., Casanueva F.F., Camiña F. Intrapersonal HbA(1c) variability and the risk of progression of nephropathy in patients with type 2 diabetes. Diabet Med 2012, 29(December (12)):1562-1566.
45. Sugawara A., Kawai K., Motohashi S., Saito K., Kodama S., Yachi Y., et al. HbA(1c) variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2. Diabetologia 2012, 55(August (8)):2128-2131.
46. Penno G., Solini A., Zoppini G., Orsi E., Fondelli C., Zerbini G., et al. Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Cardiovasc Diabetol 2013, 12(July (5)):98.
47. Kilpatrick E.S., Rigby A.S., Atkin S.L. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 2008, 31:2198-2202.
48. Hietala K., Wadén J., Forsblom C., Harjutsalo V., Kytö J., Summanen P., et al. HbA1c variability is associated with an increased risk of retinopathy requiring laser treatment in type 1 diabetes. Diabetologia 2013, 56(April (4)):737-745.
49. Hermann J.M., Hammes H.P., Rami-Merhar B., Rosenbauer J., Schütt M., Siegel E., et al. HbA1c variability as an independent risk factor for diabetic retinopathy in type 1 diabetes: a German/Austrian multicenter analysis on 35,891 patients. PLoS ONE 2014, 9(March (3)):e91137.
50. Kilpatrick E.S., Rigby A.S., Atkin S.L. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006, 29:1486-1490.
51. Kilpatrick E.S., Rigby A.S., Atkin S.L. Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care 2009, 32:1901-1903.
52. Siegelaar S.E., Kilpatrick E.S., Rigby A.S., Atkin S.L., Hoekstra J.B., Devries J.H. Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia 2009, 52:2229-2232.
53. Kilpatrick E.S., Rigby A.S., Atkin S.L. Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in patients with type 1 diabetes. Diabetologia 2008, 51:365-371.
54. Houssay S., Alvarinas J.H., Burlando G., Gonzalez C., Garcia A., Vasta S. The relation of heart rate variability with glycemic variability in type 1 diabetic patients. 2011 Diabetes. Conference: 71st scientific sessions of the American Diabetes Association San Diego 2011, [abstract].
55. Sartore G., Chilelli N.C., Burlina S., Lapolla A. Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes. Acta Diabetol 2013, 50(June (3)):437-442.
56. Siegelaar S.E., Kerr L., Jacober S.J., Devries J.H. A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction: a reanalysis of the HEART2D study. Diabetes Care 2011, 34:855-857.
57. Su G., Mi S., Tao H., Li Z., Yang H., Zheng H., et al. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 2011, 10:19.
58. Takao T., Ide T., Yanagisawa H., Kikuchi M., Kawazu S., Matsuyama Y. The effect of fasting plasma glucose variability on the risk of retinopathy in type 2 diabetic patients: retrospective long-term follow-up. Diabetes Res Clin Pract 2010, 89:296-302.
59. Abbatecola A.M., Rizzo M.R., Barbieri M., Grella R., Arciello A., Laieta M.T., et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 2006, 67:235-240.
60. Krinsley J.S. Glycemic variability and mortality in critically ill patients: the impact of diabetes. J Diabetes Sci Technol 2009, 3:1292-1301.
61. Gimeno-Orna J.A., Castro-Alonso F.J., Boned-Juliani B., Lou-Arnal L.M. Fasting plasma glucose variability as a risk factor of retinopathy in type 2 diabetic patients. J Diabetes Complications 2003, 17:78-81.
62. Klindukhova O., Chandra P., Ping L. Glycemic variability and clinical outcomes in general surgery patients. 2011 Diabetes. Conference: 71st scientific sessions of the American Diabetes Association San Diego 2011, [abstract].
63. Takao T., Ide T., Yanagisawa H., Kikuchi M., Kawazu S., Matsuyama Y. The effects of fasting plasma glucose variability and time-dependent glycemic control on the long-term risk of retinopathy in type 2 diabetic patients. Diabetes Res Clin Pract 2011, 91:e40-e42.
64. Zoppini G., Verlato G., Targher G., Casati S., Gusson E., Biasi V., et al. Is fasting glucose variability a risk factor for retinopathy in people with type 2 diabetes?. Nutr Metab Cardiovasc Dis 2009, 19:334-339.